CpG dinucleotide methylation of the SPDEF gene as a blood-based epigenetic biomarker for prostate cancer diagnosis.
1/5 보강
[BACKGROUND] Prostate cancer (PCa) is the second most commonly diagnosed malignancy in men and is projected to cause approximately 35,250 deaths in 2024.
- p-value p < 0.0001
- Sensitivity 98.3%
- Specificity 55%
APA
Ahmadianpour MV, Aleyasin SA (2025). CpG dinucleotide methylation of the SPDEF gene as a blood-based epigenetic biomarker for prostate cancer diagnosis.. BMC urology, 25(1), 145. https://doi.org/10.1186/s12894-025-01824-5
MLA
Ahmadianpour MV, et al.. "CpG dinucleotide methylation of the SPDEF gene as a blood-based epigenetic biomarker for prostate cancer diagnosis.." BMC urology, vol. 25, no. 1, 2025, pp. 145.
PMID
40457266 ↗
Abstract 한글 요약
[BACKGROUND] Prostate cancer (PCa) is the second most commonly diagnosed malignancy in men and is projected to cause approximately 35,250 deaths in 2024. The utility of total prostate-specific antigen (PSA) testing as a routine screening tool remains controversial due to limited specificity. Therefore, the identification of novel, noninvasive biomarkers is essential for improving early diagnosis. This study aimed to evaluate the methylation status of a specific CpG dinucleotide within the SPDEF (SAM-pointed domain-containing ETS transcription factor) gene promoter in blood leukocytes of PCa patients, using benign prostatic hyperplasia (BPH) samples as a control group.
[METHODS] Peripheral blood samples were collected from 360 men, including 180 diagnosed with PCa and 180 with BPH. A target CpG dinucleotide (cg11346722) in the SPDEF promoter was selected based on analysis of The Cancer Genome Atlas (TCGA) data. Methylation levels were assessed using methylation-sensitive restriction enzyme PCR (MSRE-PCR) and quantitative PCR (qPCR). Associations between methylation and clinical parameters-tumor stage (TS), histological grade, and total PSA levels-were analyzed.
[RESULTS] The mean methylation level at the SPDEF CpG site was significantly lower in PCa patients (hypomethylation: 92 ± 11.76%) compared to BPH controls (15.5 ± 15.12%) (p < 0.0001). Receiver operating characteristic (ROC) curve analysis demonstrated that SPDEF hypomethylation discriminated PCa from BPH with 98.3% sensitivity and 98.3% specificity at a < 55% methylation cutoff. A significant inverse correlation was observed between SPDEF methylation and both tumor stage (TS) and grade, whereas no correlation was found with total PSA levels.
[CONCLUSIONS] Hypomethylation of a specific CpG dinucleotide in the SPDEF promoter may serve as a promising noninvasive blood-based biomarker for the early detection and clinical stratification of prostate cancer.
[METHODS] Peripheral blood samples were collected from 360 men, including 180 diagnosed with PCa and 180 with BPH. A target CpG dinucleotide (cg11346722) in the SPDEF promoter was selected based on analysis of The Cancer Genome Atlas (TCGA) data. Methylation levels were assessed using methylation-sensitive restriction enzyme PCR (MSRE-PCR) and quantitative PCR (qPCR). Associations between methylation and clinical parameters-tumor stage (TS), histological grade, and total PSA levels-were analyzed.
[RESULTS] The mean methylation level at the SPDEF CpG site was significantly lower in PCa patients (hypomethylation: 92 ± 11.76%) compared to BPH controls (15.5 ± 15.12%) (p < 0.0001). Receiver operating characteristic (ROC) curve analysis demonstrated that SPDEF hypomethylation discriminated PCa from BPH with 98.3% sensitivity and 98.3% specificity at a < 55% methylation cutoff. A significant inverse correlation was observed between SPDEF methylation and both tumor stage (TS) and grade, whereas no correlation was found with total PSA levels.
[CONCLUSIONS] Hypomethylation of a specific CpG dinucleotide in the SPDEF promoter may serve as a promising noninvasive blood-based biomarker for the early detection and clinical stratification of prostate cancer.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.